Tags

  • Sorting

  • Filters

Top 7 Echo® MS System customer questions—answered

You asked, we answered! The Echo® MS System launched earlier this year, and has created a buzz in the industry, with analysis speeds of up to 3 samples per second. This is up to 50x faster than the conventional LC-MS/MS.  This revolutionary tool for drug discovery and...

Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?

Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?

For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.

Elimination of Interference using the SelexION Differential Mobility System for the Quantitation of Rituximab in a Dual Surrogate Peptide Approach

Elimination of Interference using the SelexION Differential Mobility System for the Quantitation of Rituximab in a Dual Surrogate Peptide Approach

The quantitation of proteins using the surrogate peptide approach can complicate nominal mass Triple Quadrupole MRM measurements due to co-extracted interference when using non-selective extraction techniques such as pellet digestion. High resolution coupled with accurate mass filtering can mitigate such interference, as reported previously for the determination of rituximab using the TripleTOF 6600 (Protein Quant Approaches). However, an additional level of selectivity can often be achieved on nominal mass systems using the orthogonal gas-phase separation approach offered by the SelexION+® Differential Mobility System technology (DMS). Interfaced between the sampling orifice and ion source, the DMS separates ions based upon differences in their migration rates under alternating low and high field waveform amplitudes (Figure 1). Ion clustering in low fields and declustering in high fields amplifies the distinction in mobility of an ion, resulting in improved resolution from interfering species of differing molecular cross-section.1-4

Host Cell Protein Analysis – Mass Spec’s Edge Over ELISA

Host Cell Protein Analysis – Mass Spec’s Edge Over ELISA

The number of protein based drugs coming onto the market is at an all-time high, particularly those produced with a host cell system. With host cells come their own proteins. These host cell proteins (HCPs) constitute a major part of process-related impurities and can adversely affect drug safety, so it is critical that they are identified and quantified accurately.

Delivering New Biologics to the Marketplace

Delivering New Biologics to the Marketplace

Characterization and quantification of host cell proteins (HCPs) in biopharmaceutical development and manufacturing is a critical step to ensuring product safety. While this can be achieved using ELISA, mass spectrometry using the SCIEX TripleTOF® 6600 System is more specific and enables the identification and quantitation of each of the individual proteins present.